Paushak
BSE: PAUSHAKLTD · Specialty Chemicals
Snapshot
Unlock Paushak's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Paushak Ltd. is a specialty chemicals company specialising in the development and manufacturing of phosgene-based derivatives. Its product portfolio includes chloroformates, isocyanates, carbonates, and chlorides, serving various industrial applications.
Geography mix
- NaN%
- NaN%
Business Model
The company generates revenue through the production and sale of complex chemical intermediates, leveraging its expertise in phosgene chemistry. It operates as a key supplier for downstream industries requiring specialised chemical building blocks.
Growth Outlook
Growth is driven by the increasing demand for phosgene-based intermediates in the pharmaceutical and agrochemical sectors. The company continues to focus on process optimisation and expanding its specialised product range.
Key Risks
- Regulatory and Environmental Compliance. As a manufacturer of hazardous phosgene-based chemicals, the company faces stringent environmental regulations and safety standards.
- Raw Material Price Volatility. Fluctuations in the prices of key chemical feedstocks can significantly impact operating margins.
- Operational Hazards. The handling of highly toxic phosgene gas presents inherent operational risks that require rigorous safety protocols and infrastructure maintenance.
- Geopolitical and Export Risks. Exposure to international markets subjects the company to risks associated with global supply chain disruptions and trade policy changes.
Start your research today
Unlock AI insights, financials, peers and live data on Paushak and 5,000+ companies — free.
Key Metrics
REVENUE
₹219 Cr
TTM · standalone
NET PROFIT
₹39 Cr
TTM · standalone
EPS
₹74.55
TTM · standalone
RETURN ON EQUITY
8.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
9.5%
TTM · standalone
P/E
10.5x
Q4 FY26 · standalone
EV/EBITDA
27.6x
Q4 FY26 · standalone
EBITDA MARGIN
33.3%
TTM · standalone
NET PROFIT MARGIN
22.7%
Q4 FY26 · standalone
DEBT TO EQUITY
0.2%
Q4 FY26 · standalone
Peers · Specialty Chemicals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
PaushakPAUSHAKLTD | ₹1,937 Cr | 10.54 | 27.62 | 3.6% | 33.3% | 8.3% | 9.5% | -87.1% |
S H Kelkar & Co.SHK | ₹2,088 Cr | 23.46 | 10.77 | 9.7% | 10.9% | 6.8% | 12.3% | -43.4% |
Camlin Fine Sciences LimitedCAMLINFINE | ₹1,981 Cr | 381.96 | 21.41 | 8.4% | 6.4% | 0.1% | 0.5% | -51.1% |
Titan BiotechTITANBIO | ₹1,793 Cr | 14.64 | 40.79 | 34.5% | 21.3% | 18.6% | 23.7% | -36.6% |
Oriental Aromatics LimitedOAL | ₹1,750 Cr | 329.05 | 26.71 | 13.5% | 7.5% | 0.8% | 6.4% | +51.4% |
IndokemINDOKEM | ₹1,745 Cr | — | — | — | 2.8% | — | — | +33.0% |
As of Q4 FY26
Financials
Paushak
BSE: PAUSHAKLTD · Specialty Chemicals
Snapshot
Unlock Paushak's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Paushak Ltd. is a specialty chemicals company specialising in the development and manufacturing of phosgene-based derivatives. Its product portfolio includes chloroformates, isocyanates, carbonates, and chlorides, serving various industrial applications.
Geography mix
- NaN%
- NaN%
Business Model
The company generates revenue through the production and sale of complex chemical intermediates, leveraging its expertise in phosgene chemistry. It operates as a key supplier for downstream industries requiring specialised chemical building blocks.
Growth Outlook
Growth is driven by the increasing demand for phosgene-based intermediates in the pharmaceutical and agrochemical sectors. The company continues to focus on process optimisation and expanding its specialised product range.
Key Risks
- Regulatory and Environmental Compliance. As a manufacturer of hazardous phosgene-based chemicals, the company faces stringent environmental regulations and safety standards.
- Raw Material Price Volatility. Fluctuations in the prices of key chemical feedstocks can significantly impact operating margins.
- Operational Hazards. The handling of highly toxic phosgene gas presents inherent operational risks that require rigorous safety protocols and infrastructure maintenance.
- Geopolitical and Export Risks. Exposure to international markets subjects the company to risks associated with global supply chain disruptions and trade policy changes.
Start your research today
Unlock AI insights, financials, peers and live data on Paushak and 5,000+ companies — free.
Key Metrics
REVENUE
₹219 Cr
TTM · standalone
NET PROFIT
₹39 Cr
TTM · standalone
EPS
₹74.55
TTM · standalone
RETURN ON EQUITY
8.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
9.5%
TTM · standalone
P/E
10.5x
Q4 FY26 · standalone
EV/EBITDA
27.6x
Q4 FY26 · standalone
EBITDA MARGIN
33.3%
TTM · standalone
NET PROFIT MARGIN
22.7%
Q4 FY26 · standalone
DEBT TO EQUITY
0.2%
Q4 FY26 · standalone
Peers · Specialty Chemicals
As of Q4 FY26